Brainstorm Cell Therapeutics reported $-6841000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Biogen BIIB:US USD 699.9M 615.2M
Brainstorm Cell Therapeutics BCLI:US USD -6841000 750K
Cytokinetics CYTK:US USD -127030000 3.66M
Gilead Sciences GILD:US USD 2.27B 570M
Halozyme Therapeutics HALO:US USD 74.51M 6.07M
Idera Pharmaceuticals IDRA:US USD -9327000 3.96M